PPMS patients taking Ocrevus are less likely to see progression
Having recently concluded an ORATORIO phase III clinical trial of primary progressive multiple sclerosis (PPMS) patients, Genentech’s Ocrevus (ocrelizumab) increased the number of patients found to have no experienced progression (NEP) when taking the drug...Read more - http://www.ms-uk.org/ppms-patients-taki ... ion-100317
PPMS patients taking Ocrevus are less likely to progress...
PPMS patients taking Ocrevus are less likely to progress...
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2007 Views
-
Last post by NHE
-
- 0 Replies
- 921 Views
-
Last post by NHE
-
- 0 Replies
- 9366 Views
-
Last post by NHE
-
- 0 Replies
- 1779 Views
-
Last post by Firidion
-
- 1 Replies
- 1285 Views
-
Last post by vesta
-
- 0 Replies
- 1948 Views
-
Last post by frodo
-
- 0 Replies
- 1868 Views
-
Last post by NHE
-
- 0 Replies
- 1404 Views
-
Last post by NHE
-
- 4 Replies
- 2336 Views
-
Last post by JohnC777